The bigger the better? ... or what we know and what we still need to learn about anthracycline dose per course, dose density and cumulative dose in the treatment of breast cancer

被引：22

作者：

Biganzoli, L ^{[1
]}

Piccart, MJ ^{[1
]}

机构：

[1] Inst Jules Bordet, Chemotherapy Unit, B-1000 Brussels, Belgium

来源：

ANNALS OF ONCOLOGY | 1997年 / 8卷 / 12期

关键词：

D O I：

10.1023/A:1008295432012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1177 / 1182

页数：6

共 24 条

[1] Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: A randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group [J].

Bastholt, L ;

Dalmark, M ;

Gjedde, SB ;

Pfeiffer, P ;

Pedersen, D ;

Sandberg, E ;

Kjaer, M ;

Mouridsen, HT ;

Rose, C ;

Nielsen, OS ;

Jakobsen, P ;

Bentzen, SM .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (04) :1146-1155

[2] RETRACTED: HIGH-DOSE CHEMOTHERAPY WITH HEMATOPOIETIC RESCUE AS PRIMARY-TREATMENT FOR METASTATIC BREAST-CANCER - A RANDOMIZED TRIAL (Retracted article. See vol. 19, pg. 2973, 2001) [J].

BEZWODA, WR ;

SEYMOUR, L ;

DANSEY, RD .

JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (10) :2483-2489

[3]

BONNETERRE J, 1996, P AN M AM SOC CLIN, V15, P104

[4]

BREMOND A, 1996, P AN M AM SOC CLIN, V15, P113

[5] Doubling epirubicin dose intensity (100 mg/m(2) versus 50 mg/m(2)) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer [J].

Brufman, G ;

Colajori, E ;

Ghilezan, N ;

Lassus, M ;

Martoni, A ;

Perevodchikova, N ;

Tosello, C ;

Viaro, D ;

Zielinski, C ;

Krainer, M ;

Salzer, H ;

Schuller, J ;

Dittrich, C ;

Scheithauer, W ;

Zamagni, C ;

Ambrosini, G ;

Colucci, G ;

Gentilini, P ;

Zaniboni, A ;

Pacini, P ;

Bianco, R ;

Mustacchi, G ;

DAprile, M ;

DeMatteis, A ;

Oliveira, C ;

Jordaan, J ;

Gudgeon, A ;

VanZyl, J ;

Rakowsky, E ;

Inbar, M ;

Rath, P ;

Cohen, Y ;

Shani, A ;

Fried, G ;

Hegg, R ;

Neto, AB ;

Bader, G ;

Braga, RF ;

Vitoc, C ;

Puerto, VML ;

Valle, AE ;

Salazar, JD ;

Sanchez, JC ;

Villela, GM ;

Fountzilas, G .

ANNALS OF ONCOLOGY, 1997, 8 (02) :155-162

[6] DOSE-RESPONSE RELATIONSHIP OF EPIRUBICIN-BASED 1ST-LINE CHEMOTHERAPY FOR ADVANCED BREAST-CANCER - A PROSPECTIVE RANDOMIZED TRIAL [J].

FOCAN, C ;

ANDRIEN, JM ;

CLOSON, MT ;

DICATO, M ;

DRIESSCHAERT, P ;

FOCANHENRARD, D ;

LEMAIRE, M ;

LOBELLE, JP ;

LONGREE, L ;

RIES, F .

JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (07) :1253-1263

[7]

FOUNTZILAS G, 1997, HELLENIC COOPERATIVE, V8, P1213

[8] Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: Five-year results [J].

Gianni, AM ;

Siena, S ;

Bregni, M ;

DiNicola, M ;

Orefice, S ;

Cusumano, F ;

Salvadori, B ;

Luini, A ;

Greco, M ;

Zucali, R ;

Rilke, F ;

Zambetti, M ;

Valagussa, P ;

Bonadonna, G .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2312-2321

[9] EPIRUBICIN AT 2 DOSE LEVELS WITH PREDNISOLONE AS TREATMENT FOR ADVANCED BREAST-CANCER - THE RESULTS OF A RANDOMIZED TRIAL [J].

HABESHAW, T ;

PAUL, J ;

JONES, R ;

STALLARD, S ;

STEWART, M ;

KAYE, SB ;

SOUKOP, M ;

SYMONDS, RP ;

REED, NS ;

RANKIN, EM .

JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (02) :295-304

[10] ANALYSIS OF DOSE INTENSITY FOR ADJUVANT CHEMOTHERAPY TRIALS IN STAGE-II BREAST-CANCER [J].

HRYNIUK, W ;

LEVINE, MN .

JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (08) :1162-1170

← 1 2 3 →